# BioPharma Industry Outlook

- Date: 2026-02-08
- Search: `biopharma industry outlook clinical trials 2025 2026 pdf site:mckinsey.com OR si...`
- Lang: en | Region: us-en | Time: y
- Results: 5 | PDF-only: True

---

## 1. Global Trends in R&D 2025 | IQVIA `[Trusted]` âœ…

ðŸ”— [www.iqvia.com](https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-trends-in-r-and-d-2025)

Explore IQVIA by region
As a global community, IQVIA continuously invests and commits to advancing human health.
Americas
Europe
Asia & Oceania
Middle East & Africa
Regional Thought Leadership
SOLUTIONS
Research & Development
Real World Evidence
Commercialization
Safety & Regulatory Compliance
Technologies
LIFE SCIENCE SEGMENTS
Consumer Health
Emerging Biopharma
Generics
MedTech
Pharmaceutical Manufacturers
HEALTHCARE SEGMENTS
Information Partner Services
Financial Institutions
Global Health

---

## 2. 2026 Life sciences outlook | Deloitte Insights `[Trusted]` âœ…

ðŸ”— [www.deloitte.com](https://www.deloitte.com/us/en/insights/industry/health-care/life-sciences-and-health-care-industry-outlooks/2026-life-sciences-executive-outlook.html)

Article
â€¢
11-min read
â€¢
09 December 2025
â€¢
Deloitte Center for Health Solutions
United States
United States
United States
Switzerland
Malaysia
India
The life sciences industry may be increasingly borderless, but confidence does not appear to be. According to Deloitteâ€™s 2026 Life Sciences Outlook Survey, more than 75% of responding biopharma and medtech executives are confident in their own organizationsâ€™ financial outlooks for the coming year.

---

## 3. 2026 Biopharma Outlook Infographic | Key Trends, Launches ... `[Trusted]` âœ…

ðŸ”— [www.evaluate.com](https://www.evaluate.com/thought-leadership/2026-biopharma-outlook-infographic/)

Biotech is back! But itâ€™s not quite as simple as that.
After years of volatility, the sector heads into 2026 with a renewed sense of possibility, buoyed by resurgent markets, intensified metabolic health competition, and the first tremors of a looming $300bn patent cliff.

---

## 4. EY 2025 Biotech Beyond Borders Report: Biopharma `[Trusted]` âœ…

ðŸ”— [www.ey.com](https://www.ey.com/en_us/newsroom/2025/06/ey-2025-biotech-beyond-borders-report-biopharma)

- Shifting policy environment creates regulatory and funding challenges: Policy changes will continue to cause uncertainty for the broader industry and investors, including NIH funding, FDAâ€™s ability to timely approve products, potential tariff implications, FTCâ€™s challenge to the Intellectual Property (IP) and CMSâ€™ impact on drug pricing with Most Favored Nations policy alongside the IRA rebates.

---

## 5. 2026 Preview | Pharma Strategy Report | Evaluate `[Trusted]` âœ…

ðŸ”— [www.evaluate.com](https://www.evaluate.com/thought-leadership/2026-preview/)

2026 Preview: Navigating Pharmaâ€™s Critical Year
The biopharma sector enters 2026 in qualified recovery. After years of tough financing and investor skepticism, green shoots are appearing, but not everyone benefits from the rebound.
This isnâ€™t another boom. The industry emerging from the drought is smarter, leaner, and more selective. For the rally to build momentum, execution matters.

---

